leon Secures Series B Funding to Accelerate Growth in Enabling Nano Now, While Establishing Strategic Partnership with Evotec
leon-nanodrugs GmbH, the leading enabler of nano technology for the pharmaceutical industry, announced today that it has successfully completed a Series B funding round. The capital will be used to further strengthen the company’s leadership position in the provision of nano solutions for the pharmaceutical and biotechnology industries.
Under a separate partnership agreement, Evotec and leon will leverage their combined expertise in nano-medicine development services, providing clients with world class, end to end opportunities within the CDMO sector. Together, the partnership will maximize the effectiveness of clinical and commercial nano-medicine development and co-operate on carefully selected development programs.
Andrea Cusack, CEO of leon commented “We are at the forefront of innovation in the international pharmaceutical market, leading the way in nano formulation of API’s. The strategic partnership with Evotec enables us to exploit the value of our technology and deliver a solution to clients from concept to GMP, successfully delivering products to market”
Dr Werner Lanthaler, Chief Executive Officer of Evotec, said: “We are excited about this new strategic collaboration with leon-nanodrugs. leon’s proprietary technology has the potential to be a game changer for the formulation, development and production of efficient drugs and will drive innovation efficiency by directly improving clinical outcomes. Our joint efforts in nanomedicine will ultimately benefit a large number of patients across a broad range of indications with significant unmet medical need.”
Christian Nafe, CFO of leon on the successful completion of the financing round: "We are encouraged by the positive participation of our new investors and the continued support of our existing consortium. This Series B funding will help us execute our strategy and bring products from the platform to the clinic.”
The investors come from right across the life sciences space, bringing a wealth of expertise and experience and includes TVM Life Science Innovation I.L.P., CD-Venture GmbH, Albany Private Equity Holdings Pty Ltd, Eckenstein-Geigy-Stiftung, LOF Leon Partnership, L.P., Evotec SE and BayBG.
Enno Spillner, CFO of Evotec and Dr. Peter Graf, Investment Manager of BayBG will join a peer recognized supervisory board which includes Dr. Hubert Birner (Managing Partner of TVM Life Science Venture Capital), Dr Gerhard Ries (LifeCare Partners), James C. Gale (Signet Healthcare Partners) and Dr. Frank Mathias (Rentschler Biotechnologie GmbH).
It is estimated that over 80% of pharmaceutical pipeline API’s are poorly soluble in water. Leon expedites Active Pharmaceutical Ingredients (APIs) to deliver improved stability, increased solubility and enhanced bioavailability, the benefits of which is lower dose, greater payload and faster onset. Leon’s novel validated and optimized solutions therefore create value for virtual companies and multinational Pharmaceutical organizations and ultimately provide better outcomes for patients.
About leon
leon delivers novel, validated and optimized solutions that create value for clients and provide better outcomes for their patients. It expedites API’s to deliver enhanced bioavailability, increased solubility and improved stability, revitalizing forgotten formulations, and breathing new life into generics.
leon’s proprietary* technology platforms offer access to the next generation of SMART nanoparticles™ and nano-formulated drugs, adding value at every stage of the chain from partners and payers to caregivers and patients.
* MicroJet Reactor (MJR)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200415005554/en/
Contact information
For more information
Andrea Cusack
CEO
leon-nanodrugs GmbH
T +49 (89) 41 42 488 981
E a.cusack@leon-nanodrugs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options4.6.2025 21:19:00 EEST | Press release
Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. This phase II study funded by Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, evaluates the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases and leptomeningeal disease, serious complications associated with advanced stages of the cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604087994/en/ Dr. Matthias Preusser during Oral Presentation of TUXEDO-3 at ASCO 2025 The study was carried out to evaluate HER3-DXd in patients with metastatic breast cancer (mBC) and advanced non-small cell lung cancer (aNSCLC) with active brain metastases, and patients with leptomeningeal disease from solid tumors. This is an antibody-drug conjugate to target HER3, a protein re
QPS Celebrates 30 th Anniversary4.6.2025 19:00:00 EEST | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to provide high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS is now recognized as a global leader in contract research. Over the past 30 years, the company has grown from a single office in Delaware, USA to a widely respected, global, full-service CRO with 8 locations spread across the US, EU, Asia, India and Australia, a clinical trial network of over 700 sites and an increased focus on leveraging the power of AI to accelerate clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604778675/en/ Dr. Benjamin Chien founder and CEO of QPS Holdings, LLC. Over the years, QPS has grown from a small molecule bioanalysis shop of three people to a globa
Cessna SkyCourier Combi Configuration Achieves Certification From the National Civil Aviation Agency of Brazil4.6.2025 18:30:00 EEST | Press release
The Cessna SkyCourier Combi configuration kit recently achieved certification from the National Civil Aviation Agency of Brazil (ANAC) and joined the fleet of Brazilian charter company Cleiton Táxi Aéreo (CTA). This marks the first delivery of the SkyCourier into South America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604928791/en/ The Cessna SkyCourier Combi configuration kit recently achieved certification from the National Civil Aviation Agency of Brazil (ANAC) and joined the fleet of Brazilian charter company Cleiton Táxi Aéreo (CTA). This marks the first delivery of the SkyCourier into South America. (Photo credit: Textron Aviation) The Cessna SkyCourier is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. CTA recently took delivery of a passenger variant of the twin-engine, large-utility turboprop equipped with conversion kits that enable the standard 19-passenger interior
IFF Unveils Game-Changing Outlook on GLP-1 Consumers4.6.2025 18:00:00 EEST | Press release
IFF (NYSE: IFF), a global leader in food, beverage, and health and wellness, has released a new report highlighting how the rapidly growing GLP-1 consumer market is reshaping the sensory experience and nutritional needs associated with eating and drinking. The report outlines how food and beverage manufacturers can better support this emerging consumer segment with products that align with their evolving preferences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604818126/en/ “IFF is empowering our customers to lead the next wave of food and beverage innovations beyond traditional formulations, including helping GLP-1 consumers have choices they desire,” said Erik Fyrwald, IFF CEO. “We aim to bring back the joy of eating and drinking by offering more healthy, great-tasting nutrition choices for all consumer segments, including GLP-1 users.” Disconnect on three levels Despite the rapid rise in GLP-1 medication use, most f
Visa Cash App Racing Bulls (VCARB) Formula One™ Team Accelerates Racing Car Design with Neural Concept’s Engineering AI4.6.2025 17:04:00 EEST | Press release
Visa Cash App Racing Bulls Formula One™Team has deployed Neural Concept, the world’s leading AI platform for engineering design to accelerate the team’s car design and optimize aerodynamic performance through AI-powered, data-driven engineering workflows that enable faster design iteration and better-informed decisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603592297/en/ Visa Cash App Red Bull - Racing Bulls and Neural Concept AI F1 vehicle partnership Neural Concept’s proprietary Engineering AI platform complements traditional Computational Fluid Dynamics (CFD) with high-speed predictive simulations. Engineers can use digital twins to evaluate thousands of design variants across complex “multi-physics” environments that mimic real-world track conditions such as wind and temperature differences. This enables VCARB to explore more designs, unlocking new performance gains within every iteration. Laurent Mekies, Tea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom